Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 27.45 as of 2026-10-06T18:56:09.741Z.
Consensus retrieved: 2026-10-06T10:04:36.869Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:56:09.741Z.
Quote observation: 2026-10-06T18:55:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 13d5cc61087bcd5172c5df40df9c3e299dfe1ccdcfacb169e2eea5995ea17995
Forward PE Ratio (27.45) = Dated Quote Price ($9.35) / Consensus Forward EPS ($0.34)
FORWARD PE RATIO
27.45
SECTOR MEDIAN · HEALTHCARE
19.88
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+38.08%
vs the sector median at left
Certara, Inc.
Market Cap
$1.45B
Forward PE Ratio
27.45
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Certara, Inc. (CERT) | $1.45B | 27.45 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 17.52 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A |
| GH Research PLC (GHRS)vs › | $1.47B | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 10.47 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.41B | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
27.4
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $9.35, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.34 | $0.32 – $0.38 | 6 | 27.4x |
| 2027-12-31 | $0.39 | $0.34 – $0.43 | 6 | 23.9x |
| 2028-12-31 | $0.44 | $-0.61 – $1.13 | 3 | 21.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
